Antiidiotypic antibodies to estradiol and gene polymorphisms of α and β estrogenic receptors in breast cancer patients
Markers for identification of ER+/PR breast cancer (BC) risks and conversion of ER+/ER+ to ER-/PR- tumors are necessary for effective prevention and therapy of BC by the selective ER – modificators. Purpose – To reveal the proposed associations of gene polymorphisms of ESR1 and ESR2 and antiidioty...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
2024-01-01
|
| Series: | Медицинская иммунология |
| Subjects: | |
| Online Access: | https://www.mimmun.ru/mimmun/article/view/2598 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839571362926034944 |
|---|---|
| author | A. N. Glushkov E. G. Polenok L. A. Gordeeva S. A. Mun A. V. Antonov P. V. Bayramov N. E. Verzhbitskaya G. I. Kolpinskiy I. A. Vafin |
| author_facet | A. N. Glushkov E. G. Polenok L. A. Gordeeva S. A. Mun A. V. Antonov P. V. Bayramov N. E. Verzhbitskaya G. I. Kolpinskiy I. A. Vafin |
| author_sort | A. N. Glushkov |
| collection | DOAJ |
| description | Markers for identification of ER+/PR breast cancer (BC) risks and conversion of ER+/ER+ to ER-/PR- tumors are necessary for effective prevention and therapy of BC by the selective ER – modificators. Purpose – To reveal the proposed associations of gene polymorphisms of ESR1 and ESR2 and antiidiotypic antibodies to estradiol (IgG2-E2) with ER+/PR+ BC risk and conversion of ER+/PR+ to ER-/PR- tumors and to study the interrelations between gene variants of ESR and IgG2-E2 in healthy women and BC patients. Polymorphic loci of ESR1 (rs2234693) and ESR2 (rs4986938) were studied by the real time PCR in 370 healthy women and 1169 BC patients. Tumor tissues ER and PR were detected by the standard immunohistochemical methods. Serum IgG2-E2 were studied using non-competitive enzyme immuno-assay. TT, TC and CC genotypes of ESR1 were revealed with the equal frequency in healthy women and BC patients I stage. Homozygotes GG of ESR2 were detected rarely, but AA frequently in BC patients with ER+/PR+ tumors at the I stage, than in healthy women женщин (44.0% and 14.2% vs 52.7 and 8.4%, respectively; p=0.005). The low levels of IgG2-ES were revealed more rarely but high levels more frequently in BC patients with ER+/PR+ tumors at the I stage, that in healthy donors (39.8% and 60.2% vs 58.0% and 42.0%, respectively; p=0.0002). Decreasing of ER+/PR+ tumors proportion and corresponding increasing of ER-/PR- tumors from I stage to II–IV stages (71.7% to 58.9% and 13.9% to 23.1%; p=0.006) were revealed in TC heterozygotes of ESR1 only. The same conversion of ER+/PR+ tumors to ER-/PR- were detected in GG homozygotes of ESR2 (p=0.004). There have been the similar ER/PR transformation in BC patients with high IgG2-E2 levels (74.7% to 57.6% and 11.3%, to 25.0%, respectively, p<0.0001). High and low IgG2-E2 levels were detected with the same proportions at the any genotypes of ESR1 and ESR2 in healthy women or in BC patients. ESR1-2 gene polymorphisms and serum IgG2-E2 levels may be used as independent markers for prediction of ER+/PR+ and for ER+/PR+ to ER-/PR- tumors conversion during BC progression. |
| format | Article |
| id | doaj-art-cbb84b49fbbf4e9a95f6027f7b542eff |
| institution | Matheson Library |
| issn | 1563-0625 2313-741X |
| language | Russian |
| publishDate | 2024-01-01 |
| publisher | St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| record_format | Article |
| series | Медицинская иммунология |
| spelling | doaj-art-cbb84b49fbbf4e9a95f6027f7b542eff2025-08-04T14:30:42ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2024-01-0126115916810.15789/1563-0625-AAT-25981805Antiidiotypic antibodies to estradiol and gene polymorphisms of α and β estrogenic receptors in breast cancer patientsA. N. Glushkov0E. G. Polenok1L. A. Gordeeva2S. A. Mun3A. V. Antonov4P. V. Bayramov5N. E. Verzhbitskaya6G. I. Kolpinskiy7I. A. Vafin8Federal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of SciencesFederal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of SciencesFederal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of SciencesFederal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of SciencesKuzbass Clinical Oncology DispensaryKuzbass Clinical Oncology DispensaryKuzbass Clinical Oncology DispensaryKemerovo State Medical University; Kemerovo Clinical Diagnostic СenterKuzbass Center of BloodMarkers for identification of ER+/PR breast cancer (BC) risks and conversion of ER+/ER+ to ER-/PR- tumors are necessary for effective prevention and therapy of BC by the selective ER – modificators. Purpose – To reveal the proposed associations of gene polymorphisms of ESR1 and ESR2 and antiidiotypic antibodies to estradiol (IgG2-E2) with ER+/PR+ BC risk and conversion of ER+/PR+ to ER-/PR- tumors and to study the interrelations between gene variants of ESR and IgG2-E2 in healthy women and BC patients. Polymorphic loci of ESR1 (rs2234693) and ESR2 (rs4986938) were studied by the real time PCR in 370 healthy women and 1169 BC patients. Tumor tissues ER and PR were detected by the standard immunohistochemical methods. Serum IgG2-E2 were studied using non-competitive enzyme immuno-assay. TT, TC and CC genotypes of ESR1 were revealed with the equal frequency in healthy women and BC patients I stage. Homozygotes GG of ESR2 were detected rarely, but AA frequently in BC patients with ER+/PR+ tumors at the I stage, than in healthy women женщин (44.0% and 14.2% vs 52.7 and 8.4%, respectively; p=0.005). The low levels of IgG2-ES were revealed more rarely but high levels more frequently in BC patients with ER+/PR+ tumors at the I stage, that in healthy donors (39.8% and 60.2% vs 58.0% and 42.0%, respectively; p=0.0002). Decreasing of ER+/PR+ tumors proportion and corresponding increasing of ER-/PR- tumors from I stage to II–IV stages (71.7% to 58.9% and 13.9% to 23.1%; p=0.006) were revealed in TC heterozygotes of ESR1 only. The same conversion of ER+/PR+ tumors to ER-/PR- were detected in GG homozygotes of ESR2 (p=0.004). There have been the similar ER/PR transformation in BC patients with high IgG2-E2 levels (74.7% to 57.6% and 11.3%, to 25.0%, respectively, p<0.0001). High and low IgG2-E2 levels were detected with the same proportions at the any genotypes of ESR1 and ESR2 in healthy women or in BC patients. ESR1-2 gene polymorphisms and serum IgG2-E2 levels may be used as independent markers for prediction of ER+/PR+ and for ER+/PR+ to ER-/PR- tumors conversion during BC progression.https://www.mimmun.ru/mimmun/article/view/2598breast cancersteroid receptorsantiidiotypic antibodiesestradiolcarcinogenesisgenetic polymorphism |
| spellingShingle | A. N. Glushkov E. G. Polenok L. A. Gordeeva S. A. Mun A. V. Antonov P. V. Bayramov N. E. Verzhbitskaya G. I. Kolpinskiy I. A. Vafin Antiidiotypic antibodies to estradiol and gene polymorphisms of α and β estrogenic receptors in breast cancer patients Медицинская иммунология breast cancer steroid receptors antiidiotypic antibodies estradiol carcinogenesis genetic polymorphism |
| title | Antiidiotypic antibodies to estradiol and gene polymorphisms of α and β estrogenic receptors in breast cancer patients |
| title_full | Antiidiotypic antibodies to estradiol and gene polymorphisms of α and β estrogenic receptors in breast cancer patients |
| title_fullStr | Antiidiotypic antibodies to estradiol and gene polymorphisms of α and β estrogenic receptors in breast cancer patients |
| title_full_unstemmed | Antiidiotypic antibodies to estradiol and gene polymorphisms of α and β estrogenic receptors in breast cancer patients |
| title_short | Antiidiotypic antibodies to estradiol and gene polymorphisms of α and β estrogenic receptors in breast cancer patients |
| title_sort | antiidiotypic antibodies to estradiol and gene polymorphisms of α and β estrogenic receptors in breast cancer patients |
| topic | breast cancer steroid receptors antiidiotypic antibodies estradiol carcinogenesis genetic polymorphism |
| url | https://www.mimmun.ru/mimmun/article/view/2598 |
| work_keys_str_mv | AT anglushkov antiidiotypicantibodiestoestradiolandgenepolymorphismsofaandbestrogenicreceptorsinbreastcancerpatients AT egpolenok antiidiotypicantibodiestoestradiolandgenepolymorphismsofaandbestrogenicreceptorsinbreastcancerpatients AT lagordeeva antiidiotypicantibodiestoestradiolandgenepolymorphismsofaandbestrogenicreceptorsinbreastcancerpatients AT samun antiidiotypicantibodiestoestradiolandgenepolymorphismsofaandbestrogenicreceptorsinbreastcancerpatients AT avantonov antiidiotypicantibodiestoestradiolandgenepolymorphismsofaandbestrogenicreceptorsinbreastcancerpatients AT pvbayramov antiidiotypicantibodiestoestradiolandgenepolymorphismsofaandbestrogenicreceptorsinbreastcancerpatients AT neverzhbitskaya antiidiotypicantibodiestoestradiolandgenepolymorphismsofaandbestrogenicreceptorsinbreastcancerpatients AT gikolpinskiy antiidiotypicantibodiestoestradiolandgenepolymorphismsofaandbestrogenicreceptorsinbreastcancerpatients AT iavafin antiidiotypicantibodiestoestradiolandgenepolymorphismsofaandbestrogenicreceptorsinbreastcancerpatients |